Leap Therapeutics, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, agreed to acquire Flame Biosciences, a privately-held biotechnology company. Financial terms were not disclosed. "Flame conducted an extensive strategic process. It was clear that the Leap development team, with its expertise in developing DKN-01, was the ideal partner for FL-301, our preclinical assets, and the Flame shareholders," Patricia Martin, Flame Co-CEO.